Astrotech (ASTC) risk factors
Item 1A of every Astrotech Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors56 risks7 new9 reworded
Lunar Initiatives now dominate risk disclosure, with unproven technology, funding dependence, acquisitions, competition, and execution uncertainty.
Filed Sep 25, 2026 - FY2025 10-K risk factors49 risks1 new3 dropped14 reworded
Astrotech faces ongoing net losses and accumulated deficits while developing early-stage business units and medical devices like the BreathTest-1000. Regulatory challenges, FDA compliance, and reliance on single-source suppliers heavily influence the company's risk profile.
Filed Sep 26, 2025 - FY2024 10-K risk factors51 risks
Astrotech relies on two affiliated customers without long-term contracts and faces early-stage development risks for products like the BreathTest-1000. The company has an accumulated deficit of $237 million and needs additional capital to fund operations. Its equipment sales are tied to the federally illegal hemp and cannabis industry.
Filed Sep 20, 2024